Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anuraag R Kansal

Showing results (1-10 of 32) with videos related to

Pageof 4
Sort By:
Diabetes Technology & Therapeutics|March 6, 2004
Modeling approaches to type 2 diabetesAnuraag R Kansal
Journal of Medical Economics|September 22, 2015
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in CanadaEmily Dorman, Anuraag R Kansal, Sujata Sarda
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|November 22, 2002
Diversity of order and densities in jammed hard-particle packingsAnuraag R Kansal, Salvatore Torquato, Frank H Stillinger
Best Practice & Research. Clinical Haematology|August 20, 2013
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillationAnuraag R Kansal, Ying Zheng, Tiffany Pokora, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 25, 2018
Alzheimer's disease Archimedes condition-event simulator: Development and validationAnuraag R Kansal, Ali Tafazzoli, K Jack Ishak, et al.
Applied Health Economics and Health Policy|October 4, 2012
Inclusion of compliance and persistence in economic models: past, present and futureAnanth Kadambi, Robert J Leipold, Anuraag R Kansal, et al.
JAMA Network Open|May 26, 2023
Assessment of Medical and Public Assistance Expenditures and Employment Among US Adults With Cancer DiagnosesDavid C Grabowski, Anuraag R Kansal, Dana P Goldman, et al.
Pharmacoeconomics|April 26, 2013
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillationSonja V Sorensen, Siyang Peng, Brigitta U Monz, et al.
Journal of Medical Economics|September 17, 2013
Modeling hard clinical end-point data in economic analysesAnuraag R Kansal, Ying Zheng, Roberto Palencia, et al.
Journal of the American Heart Association|May 8, 2016
Cost-Effectiveness of Ivabradine for Heart Failure in the United StatesAnuraag R Kansal, Martin R Cowie, Adrian Kielhorn, et al.
Pageof 4

Showing results (1-10 of 32) with videos related to

Sort By:
Pageof 4
Diabetes Technology & Therapeutics|March 6, 2004
Modeling approaches to type 2 diabetesAnuraag R Kansal
Journal of Medical Economics|September 22, 2015
The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in CanadaEmily Dorman, Anuraag R Kansal, Sujata Sarda
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics|November 22, 2002
Diversity of order and densities in jammed hard-particle packingsAnuraag R Kansal, Salvatore Torquato, Frank H Stillinger
Best Practice & Research. Clinical Haematology|August 20, 2013
Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillationAnuraag R Kansal, Ying Zheng, Tiffany Pokora, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 25, 2018
Alzheimer's disease Archimedes condition-event simulator: Development and validationAnuraag R Kansal, Ali Tafazzoli, K Jack Ishak, et al.
Applied Health Economics and Health Policy|October 4, 2012
Inclusion of compliance and persistence in economic models: past, present and futureAnanth Kadambi, Robert J Leipold, Anuraag R Kansal, et al.
JAMA Network Open|May 26, 2023
Assessment of Medical and Public Assistance Expenditures and Employment Among US Adults With Cancer DiagnosesDavid C Grabowski, Anuraag R Kansal, Dana P Goldman, et al.
Pharmacoeconomics|April 26, 2013
A comparative analysis of models used to evaluate the cost-effectiveness of dabigatran versus warfarin for the prevention of stroke in atrial fibrillationSonja V Sorensen, Siyang Peng, Brigitta U Monz, et al.
Journal of Medical Economics|September 17, 2013
Modeling hard clinical end-point data in economic analysesAnuraag R Kansal, Ying Zheng, Roberto Palencia, et al.
Journal of the American Heart Association|May 8, 2016
Cost-Effectiveness of Ivabradine for Heart Failure in the United StatesAnuraag R Kansal, Martin R Cowie, Adrian Kielhorn, et al.
Pageof 4